Leerink Partners analyst Roanna Ruiz maintained a Buy rating on NewAmsterdam Pharma Company on July 30 and set a price target of $107.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Roanna Ruiz has given her Buy rating due to a combination of factors that highlight NewAmsterdam Pharma Company’s promising developments. The company’s recent Phase 3 trial results for obicetrapib (obi) in Alzheimer’s disease (AD) biomarkers have shown a significant reduction in plasma p-tau217, which is a notable achievement compared to placebo. This result differentiates obi’s clinical profile from existing lipid-lowering therapies and suggests potential benefits beyond cardiovascular diseases.
Furthermore, the management’s strategic focus on completing the Phase 3 PREVAIL cardiovascular outcomes trial demonstrates their disciplined approach to capital allocation. The anticipated top-line data by the end of 2026 and the expected marketing authorization application filing in the EU by the end of 2025 underscore the company’s commitment to advancing obi’s development. These factors collectively enhance the clinical and commercial prospects of NewAmsterdam Pharma, justifying the Buy rating.
According to TipRanks, Ruiz is an analyst with an average return of -7.9% and a 36.55% success rate. Ruiz covers the Healthcare sector, focusing on stocks such as United Therapeutics, Amarin, and Lantheus.
In another report released yesterday, Scotiabank also maintained a Buy rating on the stock with a $52.00 price target.